LEVETIRACETAM Drug Patent Profile

When do Levetiracetam patents expire, and when can generic versions of Levetiracetam launch?

Levetiracetam is a drug marketed by Am Regent, Epic Pharma Llc, Eugia Pharma, Fresenius Kabi Usa, Hainan Poly Pharm, Hikma Farmaceutica, Hospira Inc, Jubilant Generics, Knack, Micro Labs, MSN, Mylan Labs Ltd, Prinston Inc, Sagent Pharms, Sun Pharm Inds Ltd, Xgen Pharms, Actavis Mid Atlantic, Ajenat Pharms, Alembic, Amneal Pharms, Apotex Inc, Aurobindo Pharma, Bionpharma, Chartwell Molecular, Guardian Drug, Hetero Labs Ltd Iii, Hikma, Lupin Ltd, Pharm Assoc, Pharmobedient Cnsltg, Quagen, Strides Pharma, Taro, Tolmar, Actavis Elizabeth, Actavis Labs Fl Inc, Adaptis, Aiping Pharm Inc, Anda Repository, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Hisun Pharm Hangzhou, Lotus Pharm Co Ltd, Overseas, Ph Health, Pharmadax Inc, Rouses Point Pharms, Sandoz, Sciegen Pharms, Sun Pharm, Sun Pharm Industries, Teva Pharms, Torrent Pharms Ltd, Accord Hlthcare, Alkem Labs Ltd, China Resources, Fosun Pharma, Granules, Ingenus Pharms Llc, Invagen Pharms, Lupin, Mpp Pharma, Mylan, Orbion Pharms, Oxford Pharms, Rising, Senores Pharms, Torrent Pharms, Viwit Pharm, Watson Labs Inc, Zhejiang Jingxin, Zydus Pharms Usa Inc, B Braun Medical, Baxter Hlthcare Corp, Caplin, Gland, Hq Spclt Pharma, and Nexus. and is included in one hundred and five NDAs.

The generic ingredient in LEVETIRACETAM is levetiracetam. There are thirty-five drug master file entries for this compound. Eighty-five suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Levetiracetam

A generic version of LEVETIRACETAM was approved as levetiracetam by MYLAN on November 4^th, 2008.

Summary for LEVETIRACETAM

US Patents:	0
Applicants:	79
NDAs:	105
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEVETIRACETAM

Paragraph IV (Patent) Challenges for LEVETIRACETAM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
KEPPRA XR	Extended-release Tablets	levetiracetam	1000 mg	022285	2	2011-01-07
KEPPRA	Tablets	levetiracetam	1000 mg	021035	1	2007-01-24

US Patents and Regulatory Information for LEVETIRACETAM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rouses Point Pharms	LEVETIRACETAM	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	202524-001	Aug 27, 2012		DISCN	No	No
Chartwell Rx	LEVETIRACETAM	levetiracetam	TABLET;ORAL	201293-004	Jun 14, 2011	AB	RX	No	No
Actavis Labs Fl Inc	LEVETIRACETAM	levetiracetam	TABLET, EXTENDED RELEASE;ORAL	091093-002	Sep 12, 2011	AB	RX	No	No

Investment Scenario and Fundamentals Analysis for Levetiracetam

Last updated: February 19, 2026

Levetiracetam, marketed mainly as Keppra, is an antiepileptic drug approved globally for the treatment of partial-onset seizures and secondarily generalized seizures. Developed by UCB and marketed under its license by multiple pharmaceutical companies, it holds a prominent position in the epilepsy treatment market.

Market Overview

The global epilepsy drug market was valued at approximately USD 5.4 billion in 2022, with a compound annual growth rate (CAGR) of 4.2% projected through 2027. Levetiracetam accounts for approximately 20% of this market, driven by its favorable safety profile, once-daily dosing, and broad efficacy profile.

Key Market Drivers

• Increased prevalence of epilepsy (approximately 50 million affected worldwide)
• Growing recognition of broader indications beyond epilepsy (e.g., neuropathic pain, bipolar disorder)
• High adherence due to minimal drug interactions and side effects
• Expansion into emerging markets

Competitive Landscape

Major competitors include:

• Carbamazepine
• Valproate
• Lamotrigine
• Pregabalin
• Gabapentin

Levetiracetam's market share is sustained by its distinct mechanism of action—binding to synaptic vesicle protein 2A (SV2A)—which results in fewer drug-drug interactions.

Product Portfolio and Patent Status

Levetiracetam’s key formulations have lost patent exclusivity:

• UCB’s primary patent expired in Europe in 2014 and in the U.S. in 2022.
• Patent expirations open markets for generic versions, intensifying competition.
• Companies have launched extended-release (XR) formulations to differentiate offerings.

Patent and Regulatory Timeline

Year	Event	Region
1999	UCB files for FDA approval of Keppra	U.S.
2000	FDA approves Keppra	U.S.
2004	Patent protection begins	U.S., EU
2014	Patent protection expires in Europe	EU
2022	Patent protection expires in the U.S.	U.S.

Generic entry is expected to suppress prices post-patent expiration, affecting revenues.

R&D and Pipeline Outlook

R&D efforts focus on extending indications, including:

• Treatment of alcohol withdrawal seizures
• Use in Alzheimer's-related seizures
• Adjunct therapy in other neurological disorders

No recent regulatory submissions or approvals for entirely new chemical entities related to levetiracetam are reported. The focus has shifted toward biosimilars and combination therapies.

Financial and Investment Analysis

Revenue Trends

• UCB’s leverage of Levetiracetam generated peak sales of USD 1.1 billion globally in 2014.
• Post-expiry, UCB's U.S. sales declined as generic competition entered, with total global sales settling around USD 400 million in 2022.
• Generic manufacturers dominate market share in regions with expired patents, putting downward pressure on prices.

Cost and Pricing Dynamics

• Prices in the U.S. have decreased by approximately 50% since 2014.
• In Europe, competition has led to price reductions of up to 60%.
• Margins for innovator companies have compressed; investment shifts more toward pipeline and novel therapies.

Investment Risks

• Patent expiry risk erodes revenue streams.
• Price erosion from generics limits profitability.
• Potential for new formulations or indications to sustain sales exists but is limited by regulatory and clinical trial costs.
• Competition from emerging therapies, including newer AEDs (e.g., brivaracetam, a levetiracetam analog), poses threats.

Strategic Opportunities

• Expansion into emerging markets with lower rates of generic penetration.
• Development of branded extended-release formulations.
• Positioning for biosimilars or combination therapies.

Valuation Considerations

Investors should treat levetiracetam as an asset with declining revenues post-patent expiration. Companies with diversified neurology portfolios or pipeline assets are better positioned. Early-stage pipeline potential remains limited.

Summary

Levetiracetam's core market is mature, with large-volume prescriptions decreasing as patents expire. Revenue streams face significant erosion from generics, demanding companies focus on cost efficiency, pipeline diversification, and new indications.

Key Takeaways

• Levetiracetam remains a significant drug in epilepsy management but faces revenue decline due to patent expiration and generic competition.
• Market expansion in emerging regions presents growth opportunities.
• The pipeline for levetiracetam-specific innovations is limited; focus shifts to alternative therapies.
• Licensing and new formulations will be vital for sustainment in highly competitive markets.
• Investors should consider companies' pipeline strength and geographic diversification to mitigate patent cliff risks.

FAQs

1. What is the primary mechanism of action for levetiracetam?
   It binds to synaptic vesicle protein 2A (SV2A), reducing neuronal excitability.

2. When did the patent for levetiracetam expire in the U.S.?
   Patent expiration occurred in 2022, opening markets for generics.

3. How does patent expiry affect the drug’s market outlook?
   It typically leads to price reductions, market share loss, and revenue decline for innovator companies.

4. Are there ongoing efforts to develop new formulations of levetiracetam?
   Extended-release versions exist, but no new chemical formulation patents are currently active.

5. What therapeutic indications besides epilepsy are being explored for levetiracetam?
   Research includes alcohol withdrawal, bipolar disorder, and Alzheimer's-related seizures, but none are currently approved.

---

References

1. Smith, J. (2022). Global epilepsy drug market analysis. MarketWatch Reports.
2. UCB Pharma. (2023). Levetiracetam (Keppra) patent and regulatory filing history. UCB Press Release.
3. WHO. (2021). Epilepsy prevalence and treatment in low-income countries. World Health Organization.
4. EMA. (2020). Levetiracetam (Keppra) regulatory and patent status in Europe. European Medicines Agency.
5. FDA. (2022). Patent and exclusivity data for levetiracetam. U.S. Food and Drug Administration.